These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18557213)

  • 1. [What is better here: ACE inhibitor or AT1 blocker?].
    MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
    [No Abstract]   [Full Text] [Related]  

  • 2. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M; Waeber B; Hess O; Lüscher T
    Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
    [No Abstract]   [Full Text] [Related]  

  • 5. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 8. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
    [No Abstract]   [Full Text] [Related]  

  • 9. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE inhibitors in cardiovascular disease--unbeatable?
    McMurray JJ
    N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
    [No Abstract]   [Full Text] [Related]  

  • 11. [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):14, 16. PubMed ID: 18983047
    [No Abstract]   [Full Text] [Related]  

  • 12. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 13. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 15. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 16. [The ONTARGET trial].
    Verdecchia P; Terrosu P
    G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
    [No Abstract]   [Full Text] [Related]  

  • 17. Telmisartan, ramipril, or both in patients at high risk of vascular events.
    Büchner N; Banas B; Krämer BK
    N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
    [No Abstract]   [Full Text] [Related]  

  • 18. Study at up to 700 sites will build on landmark HOPE trial.
    Cardiovasc J S Afr; 2001; 12(2):127-30. PubMed ID: 11474703
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

  • 20. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.